Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 394

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Open access
Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, Ellen L., Block, Matthew S., Kalli, Kimberly R., Vierkant, Robert A., Chen, Wenqian, Fogarty, Zachary C., Gentry-Maharaj, Aleksandra, Toloczko, Aleksandra, Hein, Alexander, Bouligny, Aliecia L., Jensen, Allan, Osorio, Ana, Hartkopf, Andreas D., Ryan, Andy, Chudecka-Glaz, Anita, Magliocco, Anthony M., Hartmann, Arndt, Jung, Audrey Y, Gao, Bo, Hernandez, Brenda Y., Fridley, Brooke L., McCauley, Bryan M., Kennedy, Catherine J., Wang, Chen, Karpinskyj, Chloe, de Sousa, Christiani B., Tiezzi, Daniel G., Wachter, David L., Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Nelson, Gregg, Lubinski, Jan, Menkiszak, Janusz, Alsop, Jennifer, Lester, Jenny, García-Donas, Jesús, Nation, Jill, Hung, Jillian, Palacios, José, Rothstein, Joseph H., Kelley, Joseph L., de Andrade, Jurandyr M., Robles-Díaz, Luis, Intermaggio, Maria P., Widschwendter, Martin, Beckmann, Matthias W., Ruebner, Matthias, Jimenez-Linan, Mercedes, Singh, Naveena, Oszurek, Oleg, Harnett, Paul R., Rambau, Peter F., Sinn, Peter, Wagner, Philipp, Ghatage, Prafull, Sharma, Raghwa, Edwards, Robert P., Ness, Roberta B., Orsulic, Sandra, Brucker, Sara Y., Johnatty, Sharon E., Longacre, Teri A., Eilber, Ursula, McGuire, Valerie, Sieh, Weiva, Natanzon, Yanina, Li, Zheng, Whittemore, Alice S., deFazio, Anna, Staebler, Annette, Karlan, Beth Y., Gilks, Blake, Bowtell, David D., Høgdall, Estrid, Candido dos Reis, Francisco J., Steed, Helen, Campbell, Ian G., Gronwald, Jacek, Benítez, Javier, Koziak, Jennifer M., Chang-Claude, Jenny, Moysich, Kirsten B., Kelemen, Linda E., Cook, Linda S., Goodman, Marc T., García, María José, Fasching, Peter A., Kommoss, Stefan, Deen, Suha, Kjaer, Susanne K., Menon, Usha, Brenton, James D., Pharoah, Paul D. P., Chenevix-Trench, Georgia, Huntsman, David G., Winham, Stacey J., Köbel, Martin, Ramus, Susan J.·2017·JAMA Oncology

Abstract

Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. Objective: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. Design, Setting, and Participants: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. Exposures: Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. Main Outcomes and Measures: Overall survival time. Results: The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. Conclusions and Relevance: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2017.3290

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 394

Metadata

Authors
Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, E. L., Block, M. S., Kalli, K. R., Vierkant, R. A., Chen, W., Fogarty, Z. C., Gentry-Maharaj, A., Toloczko, A., Hein, A., Bouligny, A. L., Jensen, A., Osorio, A., Hartkopf, A. D., Ryan, A., Chudecka-Glaz, A., Magliocco, A. M., Hartmann, A., Jung, A. Y., Gao, B., Hernandez, B. Y., Fridley, B. L., McCauley, B. M., Kennedy, C. J., Wang, C., Karpinskyj, C., de Sousa, C. B., Tiezzi, D. G., Wachter, D. L., Herpel, E., Taran, F. A., Modugno, F., Nelson, G., Lubinski, J., Menkiszak, J., Alsop, J., Lester, J., García-Donas, J., Nation, J., Hung, J., Palacios, J., Rothstein, J. H., Kelley, J. L., de Andrade, J. M., Robles-Díaz, L., Intermaggio, M. P., Widschwendter, M., Beckmann, M. W., Ruebner, M., Jimenez-Linan, M., Singh, N., Oszurek, O., Harnett, P. R., Rambau, P. F., Sinn, P., Wagner, P., Ghatage, P., Sharma, R., Edwards, R. P., Ness, R. B., Orsulic, S., Brucker, S. Y., Johnatty, S. E., Longacre, T. A., Eilber, U., McGuire, V., Sieh, W., Natanzon, Y., Li, Z., Whittemore, A. S., deFazio, A., Staebler, A., Karlan, B. Y., Gilks, B., Bowtell, D. D., Høgdall, E., Candido dos Reis, F. J., Steed, H., Campbell, I. G., Gronwald, J., Benítez, J., Koziak, J. M., Chang-Claude, J., Moysich, K. B., Kelemen, L. E., Cook, L. S., Goodman, M. T., García, M. J., Fasching, P. A., Kommoss, S., Deen, S., Kjaer, S. K., Menon, U., Brenton, J. D., Pharoah, P. D. P., Chenevix-Trench, G., Huntsman, D. G., Winham, S. J., Köbel, M., & Ramus, S. J.
Venue
JAMA Oncology
Published
2017-12-14
Volume
3
Issue
12
Pages
e173290
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2765953690
Cited by
394
References
52
FWCI
34.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. https://app.cochat.ai/papers/10.1001/jamaoncol.2017.3290
The paper
Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, E. L., Block, M. S., Kalli, K. R., Vierkant, R. A., Chen, W., Fogarty, Z. C., Gentry-Maharaj, A., Toloczko, A., Hein, A., Bouligny, A. L., Jensen, A., Osorio, A., Hartkopf, A. D., Ryan, A., Chudecka-Glaz, A., Magliocco, A. M., Hartmann, A., Jung, A. Y., . . . Ramus, S. J. (2017). Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2017.3290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.